PMC:7205724 / 29433-30161 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1061","span":{"begin":477,"end":480},"obj":"Gene"},{"id":"1062","span":{"begin":660,"end":663},"obj":"Gene"},{"id":"1063","span":{"begin":717,"end":720},"obj":"Gene"},{"id":"1064","span":{"begin":593,"end":601},"obj":"Species"},{"id":"1065","span":{"begin":698,"end":706},"obj":"Species"},{"id":"1066","span":{"begin":617,"end":628},"obj":"Chemical"},{"id":"1067","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"1068","span":{"begin":47,"end":59},"obj":"Disease"},{"id":"1069","span":{"begin":307,"end":315},"obj":"Disease"},{"id":"1070","span":{"begin":413,"end":421},"obj":"Disease"},{"id":"1071","span":{"begin":430,"end":435},"obj":"Disease"},{"id":"1072","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"1073","span":{"begin":607,"end":615},"obj":"Disease"}],"attributes":[{"id":"A1061","pred":"tao:has_database_id","subj":"1061","obj":"Gene:3569"},{"id":"A1062","pred":"tao:has_database_id","subj":"1062","obj":"Gene:3569"},{"id":"A1063","pred":"tao:has_database_id","subj":"1063","obj":"Gene:3569"},{"id":"A1064","pred":"tao:has_database_id","subj":"1064","obj":"Tax:9606"},{"id":"A1065","pred":"tao:has_database_id","subj":"1065","obj":"Tax:9606"},{"id":"A1066","pred":"tao:has_database_id","subj":"1066","obj":"MESH:C502936"},{"id":"A1067","pred":"tao:has_database_id","subj":"1067","obj":"MESH:C000657245"},{"id":"A1068","pred":"tao:has_database_id","subj":"1068","obj":"MESH:D007249"},{"id":"A1069","pred":"tao:has_database_id","subj":"1069","obj":"MESH:C000657245"},{"id":"A1070","pred":"tao:has_database_id","subj":"1070","obj":"MESH:C000657245"},{"id":"A1071","pred":"tao:has_database_id","subj":"1071","obj":"MESH:D003643"},{"id":"A1072","pred":"tao:has_database_id","subj":"1072","obj":"MESH:C000657245"},{"id":"A1073","pred":"tao:has_database_id","subj":"1073","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T213","span":{"begin":468,"end":476},"obj":"Body_part"},{"id":"T214","span":{"begin":504,"end":512},"obj":"Body_part"},{"id":"T215","span":{"begin":643,"end":651},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T221","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"T222","span":{"begin":47,"end":59},"obj":"Disease"},{"id":"T223","span":{"begin":307,"end":315},"obj":"Disease"},{"id":"T224","span":{"begin":413,"end":421},"obj":"Disease"},{"id":"T225","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"T226","span":{"begin":607,"end":615},"obj":"Disease"}],"attributes":[{"id":"A221","pred":"mondo_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A222","pred":"mondo_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A223","pred":"mondo_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A224","pred":"mondo_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A225","pred":"mondo_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T333","span":{"begin":83,"end":84},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T334","span":{"begin":630,"end":631},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T236","span":{"begin":260,"end":275},"obj":"Chemical"},{"id":"T237","span":{"begin":386,"end":401},"obj":"Chemical"}],"attributes":[{"id":"A236","pred":"chebi_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A237","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T30","span":{"begin":564,"end":574},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A30","pred":"meddra_id","subj":"T30","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T143","span":{"begin":205,"end":221},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T151","span":{"begin":260,"end":275},"obj":"Chemical"},{"id":"T152","span":{"begin":386,"end":401},"obj":"Chemical"}],"attributes":[{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T271","span":{"begin":15,"end":23},"obj":"Species"},{"id":"T272","span":{"begin":307,"end":315},"obj":"Species"},{"id":"T273","span":{"begin":413,"end":421},"obj":"Species"},{"id":"T274","span":{"begin":516,"end":524},"obj":"Species"},{"id":"T275","span":{"begin":607,"end":615},"obj":"Species"}],"attributes":[{"id":"A273","pred":"ncbi_taxonomy_id","subj":"T273","obj":"NCBItxid:2697049"},{"id":"A272","pred":"ncbi_taxonomy_id","subj":"T272","obj":"NCBItxid:2697049"},{"id":"A271","pred":"ncbi_taxonomy_id","subj":"T271","obj":"NCBItxid:2697049"},{"id":"A275","pred":"ncbi_taxonomy_id","subj":"T275","obj":"NCBItxid:2697049"},{"id":"A274","pred":"ncbi_taxonomy_id","subj":"T274","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T237","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T238","span":{"begin":61,"end":117},"obj":"Sentence"},{"id":"T239","span":{"begin":118,"end":230},"obj":"Sentence"},{"id":"T240","span":{"begin":231,"end":316},"obj":"Sentence"},{"id":"T241","span":{"begin":317,"end":436},"obj":"Sentence"},{"id":"T242","span":{"begin":437,"end":616},"obj":"Sentence"},{"id":"T243","span":{"begin":617,"end":728},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1067","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"1068","span":{"begin":47,"end":59},"obj":"Disease"},{"id":"1069","span":{"begin":307,"end":315},"obj":"Disease"},{"id":"1070","span":{"begin":413,"end":421},"obj":"Disease"},{"id":"1071","span":{"begin":430,"end":435},"obj":"Disease"},{"id":"1061","span":{"begin":477,"end":480},"obj":"Gene"},{"id":"1072","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"1064","span":{"begin":593,"end":601},"obj":"Species"},{"id":"1073","span":{"begin":607,"end":615},"obj":"Disease"},{"id":"1066","span":{"begin":617,"end":628},"obj":"Chemical"},{"id":"1062","span":{"begin":660,"end":663},"obj":"Gene"},{"id":"1065","span":{"begin":698,"end":706},"obj":"Species"},{"id":"1063","span":{"begin":717,"end":720},"obj":"Gene"}],"attributes":[{"id":"A1062","pred":"pubann:denotes","subj":"1062","obj":"Gene:3569"},{"id":"A1061","pred":"pubann:denotes","subj":"1061","obj":"Gene:3569"},{"id":"A1069","pred":"pubann:denotes","subj":"1069","obj":"MESH:C000657245"},{"id":"A1067","pred":"pubann:denotes","subj":"1067","obj":"MESH:C000657245"},{"id":"A1063","pred":"pubann:denotes","subj":"1063","obj":"Gene:3569"},{"id":"A1073","pred":"pubann:denotes","subj":"1073","obj":"MESH:C000657245"},{"id":"A1070","pred":"pubann:denotes","subj":"1070","obj":"MESH:C000657245"},{"id":"A1065","pred":"pubann:denotes","subj":"1065","obj":"Tax:9606"},{"id":"A1071","pred":"pubann:denotes","subj":"1071","obj":"MESH:D003643"},{"id":"A1066","pred":"pubann:denotes","subj":"1066","obj":"MESH:C502936"},{"id":"A1068","pred":"pubann:denotes","subj":"1068","obj":"MESH:D007249"},{"id":"A1072","pred":"pubann:denotes","subj":"1072","obj":"MESH:C000657245"},{"id":"A1064","pred":"pubann:denotes","subj":"1064","obj":"Tax:9606"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T3157","span":{"begin":477,"end":480},"obj":"Protein"},{"id":"T3201","span":{"begin":660,"end":663},"obj":"Protein"},{"id":"T3245","span":{"begin":717,"end":720},"obj":"Protein"}],"attributes":[{"id":"A3157","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A3158","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A3159","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A3160","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A3161","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A3162","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A3163","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A3164","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A3165","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A3166","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A3167","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A3168","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A3169","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A3170","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A3171","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A3172","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A3173","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A3174","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A3175","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A3176","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A3177","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A3178","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A3179","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A3180","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A3181","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A3182","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A3183","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A3184","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A3185","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A3186","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A3187","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A3188","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A3189","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A3190","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A3191","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A3192","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A3193","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A3194","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A3195","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A3196","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A3197","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A3198","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A3199","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A3200","pred":"uniprot_id","subj":"T3157","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A3201","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A3202","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A3203","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A3204","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A3205","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A3206","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A3207","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A3208","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A3209","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A3210","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A3211","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A3212","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A3213","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A3214","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A3215","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A3216","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A3217","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A3218","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A3219","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A3220","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A3221","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A3222","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A3223","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A3224","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A3225","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A3226","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A3227","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A3228","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A3229","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A3230","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A3231","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A3232","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A3233","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A3234","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A3235","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A3236","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A3237","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A3238","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A3239","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A3240","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A3241","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A3242","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A3243","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A3244","pred":"uniprot_id","subj":"T3201","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A3245","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A3246","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A3247","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A3248","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A3249","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A3250","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A3251","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A3252","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A3253","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A3254","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A3255","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A3256","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A3257","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A3258","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A3259","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A3260","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A3261","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A3262","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A3263","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A3264","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A3265","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A3266","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A3267","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A3268","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A3269","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A3270","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A3271","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A3272","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A3273","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A3274","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A3275","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A3276","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A3277","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A3278","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A3279","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A3280","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A3281","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A3282","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A3283","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A3284","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A3285","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A3286","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A3287","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A3288","pred":"uniprot_id","subj":"T3245","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T60314","span":{"begin":0,"end":8},"obj":"NN"},{"id":"T35183","span":{"begin":9,"end":14},"obj":"VBZ"},{"id":"T72324","span":{"begin":15,"end":23},"obj":"NN"},{"id":"T95206","span":{"begin":24,"end":26},"obj":"TO"},{"id":"T97915","span":{"begin":27,"end":35},"obj":"JJ"},{"id":"T92397","span":{"begin":36,"end":43},"obj":"NNS"},{"id":"T70831","span":{"begin":44,"end":46},"obj":"IN"},{"id":"T73708","span":{"begin":47,"end":59},"obj":"NN"},{"id":"T93832","span":{"begin":61,"end":76},"obj":"NNS"},{"id":"T86571","span":{"begin":77,"end":82},"obj":"VBP"},{"id":"T20640","span":{"begin":83,"end":84},"obj":"DT"},{"id":"T11737","span":{"begin":85,"end":91},"obj":"JJ"},{"id":"T13881","span":{"begin":92,"end":109},"obj":"JJ"},{"id":"T85869","span":{"begin":110,"end":116},"obj":"NN"},{"id":"T39590","span":{"begin":118,"end":125},"obj":"RB"},{"id":"T9841","span":{"begin":125,"end":126},"obj":"-COMMA-"},{"id":"T82570","span":{"begin":127,"end":131},"obj":"PRP"},{"id":"T33328","span":{"begin":132,"end":134},"obj":"VBP"},{"id":"T52824","span":{"begin":135,"end":138},"obj":"RB"},{"id":"T27396","span":{"begin":139,"end":146},"obj":"VB"},{"id":"T37147","span":{"begin":147,"end":154},"obj":"JJ"},{"id":"T31383","span":{"begin":155,"end":162},"obj":"NNS"},{"id":"T30144","span":{"begin":163,"end":166},"obj":"CC"},{"id":"T43608","span":{"begin":167,"end":172},"obj":"MD"},{"id":"T71924","span":{"begin":173,"end":178},"obj":"VB"},{"id":"T87293","span":{"begin":179,"end":190},"obj":"NN"},{"id":"T66079","span":{"begin":191,"end":193},"obj":"IN"},{"id":"T8269","span":{"begin":194,"end":204},"obj":"JJ"},{"id":"T52172","span":{"begin":205,"end":211},"obj":"JJ"},{"id":"T20124","span":{"begin":212,"end":221},"obj":"NNS"},{"id":"T85154","span":{"begin":222,"end":224},"obj":"RB"},{"id":"T9965","span":{"begin":225,"end":229},"obj":"RB"},{"id":"T92497","span":{"begin":231,"end":238},"obj":"NNS"},{"id":"T44468","span":{"begin":239,"end":243},"obj":"VBP"},{"id":"T92811","span":{"begin":244,"end":248},"obj":"IN"},{"id":"T62828","span":{"begin":249,"end":252},"obj":"DT"},{"id":"T64812","span":{"begin":253,"end":256},"obj":"NN"},{"id":"T90977","span":{"begin":257,"end":259},"obj":"IN"},{"id":"T15178","span":{"begin":260,"end":275},"obj":"NNS"},{"id":"T25429","span":{"begin":276,"end":281},"obj":"MD"},{"id":"T69842","span":{"begin":282,"end":292},"obj":"VB"},{"id":"T80684","span":{"begin":293,"end":301},"obj":"NN"},{"id":"T88404","span":{"begin":302,"end":306},"obj":"IN"},{"id":"T21137","span":{"begin":307,"end":315},"obj":"NN"},{"id":"T1899","span":{"begin":317,"end":322},"obj":"EX"},{"id":"T21793","span":{"begin":323,"end":326},"obj":"VBP"},{"id":"T48698","span":{"begin":327,"end":329},"obj":"DT"},{"id":"T88569","span":{"begin":330,"end":340},"obj":"JJ"},{"id":"T72804","span":{"begin":341,"end":349},"obj":"JJ"},{"id":"T97339","span":{"begin":350,"end":356},"obj":"NNS"},{"id":"T48573","span":{"begin":357,"end":361},"obj":"WDT"},{"id":"T30904","span":{"begin":362,"end":366},"obj":"VBP"},{"id":"T93994","span":{"begin":367,"end":374},"obj":"IN"},{"id":"T4378","span":{"begin":375,"end":378},"obj":"DT"},{"id":"T44216","span":{"begin":379,"end":382},"obj":"NN"},{"id":"T95916","span":{"begin":383,"end":385},"obj":"IN"},{"id":"T36033","span":{"begin":386,"end":401},"obj":"NNS"},{"id":"T95640","span":{"begin":402,"end":405},"obj":"MD"},{"id":"T86415","span":{"begin":406,"end":412},"obj":"VB"},{"id":"T37383","span":{"begin":413,"end":429},"obj":"JJ"},{"id":"T11797","span":{"begin":430,"end":435},"obj":"NN"},{"id":"T74879","span":{"begin":437,"end":445},"obj":"RB"},{"id":"T90599","span":{"begin":445,"end":446},"obj":"-COMMA-"},{"id":"T98284","span":{"begin":447,"end":450},"obj":"DT"},{"id":"T49609","span":{"begin":451,"end":467},"obj":"JJ"},{"id":"T24072","span":{"begin":468,"end":476},"obj":"NN"},{"id":"T64274","span":{"begin":477,"end":480},"obj":"NN"},{"id":"T39845","span":{"begin":481,"end":483},"obj":"VBZ"},{"id":"T48453","span":{"begin":484,"end":487},"obj":"DT"},{"id":"T6053","span":{"begin":488,"end":503},"obj":"JJ"},{"id":"T54874","span":{"begin":504,"end":512},"obj":"NN"},{"id":"T84071","span":{"begin":513,"end":515},"obj":"IN"},{"id":"T3462","span":{"begin":516,"end":524},"obj":"NN"},{"id":"T4397","span":{"begin":525,"end":535},"obj":"VBD"},{"id":"T53541","span":{"begin":536,"end":540},"obj":"IN"},{"id":"T9169","span":{"begin":541,"end":549},"obj":"NN"},{"id":"T52339","span":{"begin":549,"end":550},"obj":"-COMMA-"},{"id":"T9027","span":{"begin":551,"end":562},"obj":"NN"},{"id":"T63816","span":{"begin":562,"end":563},"obj":"-COMMA-"},{"id":"T3842","span":{"begin":564,"end":569},"obj":"JJ"},{"id":"T33160","span":{"begin":570,"end":574},"obj":"NN"},{"id":"T71418","span":{"begin":574,"end":575},"obj":"-COMMA-"},{"id":"T44925","span":{"begin":576,"end":579},"obj":"CC"},{"id":"T24005","span":{"begin":580,"end":589},"obj":"NN"},{"id":"T43722","span":{"begin":590,"end":592},"obj":"IN"},{"id":"T77279","span":{"begin":593,"end":601},"obj":"NNS"},{"id":"T53860","span":{"begin":602,"end":606},"obj":"IN"},{"id":"T83045","span":{"begin":607,"end":615},"obj":"NN"},{"id":"T91725","span":{"begin":617,"end":628},"obj":"NNP"},{"id":"T13491","span":{"begin":628,"end":629},"obj":"-COMMA-"},{"id":"T55969","span":{"begin":630,"end":631},"obj":"DT"},{"id":"T88153","span":{"begin":632,"end":642},"obj":"JJ"},{"id":"T13966","span":{"begin":643,"end":651},"obj":"NN"},{"id":"T87639","span":{"begin":652,"end":659},"obj":"IN"},{"id":"T20271","span":{"begin":660,"end":663},"obj":"NN"},{"id":"T22072","span":{"begin":663,"end":664},"obj":"-COMMA-"},{"id":"T26781","span":{"begin":665,"end":670},"obj":"MD"},{"id":"T93033","span":{"begin":671,"end":677},"obj":"VB"},{"id":"T66151","span":{"begin":678,"end":686},"obj":"JJ"},{"id":"T39668","span":{"begin":687,"end":694},"obj":"NN"},{"id":"T93255","span":{"begin":695,"end":697},"obj":"IN"},{"id":"T16710","span":{"begin":698,"end":706},"obj":"NNS"},{"id":"T86610","span":{"begin":707,"end":711},"obj":"IN"},{"id":"T16499","span":{"begin":712,"end":716},"obj":"JJ"},{"id":"T41273","span":{"begin":717,"end":720},"obj":"NN"},{"id":"T27148","span":{"begin":721,"end":727},"obj":"NNS"}],"relations":[{"id":"R55247","pred":"arg2Of","subj":"T92397","obj":"T95206"},{"id":"R92120","pred":"arg1Of","subj":"T63816","obj":"T44925"},{"id":"R32306","pred":"arg1Of","subj":"T60314","obj":"T35183"},{"id":"R19129","pred":"arg2Of","subj":"T72324","obj":"T35183"},{"id":"R25853","pred":"arg1Of","subj":"T35183","obj":"T95206"},{"id":"R65223","pred":"arg1Of","subj":"T92397","obj":"T97915"},{"id":"R29631","pred":"arg1Of","subj":"T92397","obj":"T70831"},{"id":"R66024","pred":"arg2Of","subj":"T73708","obj":"T70831"},{"id":"R53561","pred":"arg1Of","subj":"T93832","obj":"T86571"},{"id":"R61578","pred":"arg2Of","subj":"T85869","obj":"T86571"},{"id":"R17185","pred":"arg1Of","subj":"T85869","obj":"T20640"},{"id":"R26499","pred":"arg1Of","subj":"T85869","obj":"T11737"},{"id":"R43732","pred":"arg1Of","subj":"T85869","obj":"T13881"},{"id":"R38807","pred":"arg1Of","subj":"T30144","obj":"T39590"},{"id":"R59317","pred":"arg1Of","subj":"T30144","obj":"T9841"},{"id":"R9092","pred":"arg1Of","subj":"T82570","obj":"T33328"},{"id":"R20630","pred":"arg2Of","subj":"T27396","obj":"T33328"},{"id":"R37965","pred":"arg1Of","subj":"T27396","obj":"T52824"},{"id":"R99599","pred":"arg1Of","subj":"T82570","obj":"T27396"},{"id":"R94411","pred":"arg2Of","subj":"T31383","obj":"T27396"},{"id":"R65208","pred":"arg1Of","subj":"T31383","obj":"T37147"},{"id":"R81898","pred":"arg1Of","subj":"T27396","obj":"T30144"},{"id":"R91050","pred":"arg2Of","subj":"T71924","obj":"T30144"},{"id":"R93772","pred":"arg1Of","subj":"T82570","obj":"T43608"},{"id":"R96557","pred":"arg2Of","subj":"T71924","obj":"T43608"},{"id":"R82268","pred":"arg1Of","subj":"T82570","obj":"T71924"},{"id":"R67688","pred":"arg2Of","subj":"T87293","obj":"T71924"},{"id":"R72835","pred":"arg1Of","subj":"T87293","obj":"T66079"},{"id":"R60797","pred":"arg2Of","subj":"T20124","obj":"T66079"},{"id":"R42302","pred":"arg1Of","subj":"T20124","obj":"T8269"},{"id":"R34762","pred":"arg1Of","subj":"T20124","obj":"T52172"},{"id":"R87076","pred":"arg1Of","subj":"T9965","obj":"T85154"},{"id":"R33081","pred":"arg1Of","subj":"T71924","obj":"T9965"},{"id":"R22782","pred":"arg1Of","subj":"T92497","obj":"T44468"},{"id":"R18642","pred":"arg2Of","subj":"T69842","obj":"T44468"},{"id":"R76777","pred":"arg1Of","subj":"T69842","obj":"T92811"},{"id":"R96241","pred":"arg1Of","subj":"T64812","obj":"T62828"},{"id":"R57789","pred":"arg1Of","subj":"T64812","obj":"T90977"},{"id":"R42521","pred":"arg2Of","subj":"T15178","obj":"T90977"},{"id":"R52693","pred":"arg1Of","subj":"T64812","obj":"T25429"},{"id":"R75916","pred":"arg2Of","subj":"T69842","obj":"T25429"},{"id":"R43795","pred":"arg1Of","subj":"T64812","obj":"T69842"},{"id":"R20459","pred":"arg2Of","subj":"T80684","obj":"T69842"},{"id":"R86356","pred":"arg1Of","subj":"T80684","obj":"T88404"},{"id":"R21604","pred":"arg2Of","subj":"T21137","obj":"T88404"},{"id":"R43872","pred":"arg1Of","subj":"T1899","obj":"T21793"},{"id":"R66576","pred":"arg2Of","subj":"T97339","obj":"T21793"},{"id":"R77390","pred":"arg1Of","subj":"T97339","obj":"T48698"},{"id":"R65755","pred":"arg1Of","subj":"T72804","obj":"T88569"},{"id":"R38259","pred":"arg1Of","subj":"T97339","obj":"T72804"},{"id":"R69637","pred":"arg1Of","subj":"T97339","obj":"T48573"},{"id":"R29960","pred":"arg1Of","subj":"T97339","obj":"T30904"},{"id":"R57398","pred":"arg2Of","subj":"T86415","obj":"T30904"},{"id":"R33558","pred":"arg1Of","subj":"T86415","obj":"T93994"},{"id":"R72524","pred":"arg1Of","subj":"T44216","obj":"T4378"},{"id":"R7741","pred":"arg1Of","subj":"T44216","obj":"T95916"},{"id":"R74181","pred":"arg2Of","subj":"T36033","obj":"T95916"},{"id":"R85296","pred":"arg1Of","subj":"T44216","obj":"T95640"},{"id":"R35205","pred":"arg2Of","subj":"T86415","obj":"T95640"},{"id":"R35783","pred":"arg1Of","subj":"T44216","obj":"T86415"},{"id":"R54861","pred":"arg2Of","subj":"T11797","obj":"T86415"},{"id":"R14968","pred":"arg1Of","subj":"T11797","obj":"T37383"},{"id":"R65897","pred":"arg1Of","subj":"T39845","obj":"T74879"},{"id":"R46266","pred":"arg1Of","subj":"T39845","obj":"T90599"},{"id":"R45534","pred":"arg1Of","subj":"T64274","obj":"T98284"},{"id":"R76858","pred":"arg1Of","subj":"T64274","obj":"T49609"},{"id":"R33432","pred":"arg1Of","subj":"T64274","obj":"T24072"},{"id":"R50943","pred":"arg1Of","subj":"T64274","obj":"T39845"},{"id":"R49022","pred":"arg2Of","subj":"T54874","obj":"T39845"},{"id":"R47959","pred":"arg1Of","subj":"T54874","obj":"T48453"},{"id":"R12734","pred":"arg1Of","subj":"T54874","obj":"T6053"},{"id":"R7429","pred":"arg1Of","subj":"T54874","obj":"T84071"},{"id":"R83809","pred":"arg2Of","subj":"T44925","obj":"T84071"},{"id":"R87187","pred":"arg2Of","subj":"T3462","obj":"T4397"},{"id":"R92110","pred":"arg1Of","subj":"T4397","obj":"T53541"},{"id":"R68265","pred":"arg2Of","subj":"T9169","obj":"T53541"},{"id":"R96435","pred":"arg1Of","subj":"T9169","obj":"T52339"},{"id":"R33111","pred":"arg2Of","subj":"T9027","obj":"T52339"},{"id":"R71697","pred":"arg1Of","subj":"T3462","obj":"T63816"},{"id":"R27015","pred":"arg2Of","subj":"T33160","obj":"T63816"},{"id":"R35581","pred":"arg1Of","subj":"T33160","obj":"T3842"},{"id":"R19463","pred":"arg1Of","subj":"T44925","obj":"T71418"},{"id":"R7472","pred":"arg2Of","subj":"T24005","obj":"T44925"},{"id":"R21271","pred":"arg1Of","subj":"T24005","obj":"T43722"},{"id":"R63382","pred":"arg2Of","subj":"T77279","obj":"T43722"},{"id":"R59863","pred":"arg1Of","subj":"T77279","obj":"T53860"},{"id":"R14281","pred":"arg2Of","subj":"T83045","obj":"T53860"},{"id":"R83532","pred":"arg1Of","subj":"T91725","obj":"T13491"},{"id":"R16595","pred":"arg2Of","subj":"T13966","obj":"T13491"},{"id":"R73426","pred":"arg1Of","subj":"T13966","obj":"T55969"},{"id":"R70938","pred":"arg1Of","subj":"T13966","obj":"T88153"},{"id":"R83956","pred":"arg1Of","subj":"T13966","obj":"T87639"},{"id":"R94996","pred":"arg2Of","subj":"T20271","obj":"T87639"},{"id":"R94172","pred":"arg1Of","subj":"T93033","obj":"T22072"},{"id":"R9162","pred":"arg1Of","subj":"T91725","obj":"T26781"},{"id":"R79231","pred":"arg2Of","subj":"T93033","obj":"T26781"},{"id":"R97743","pred":"arg1Of","subj":"T91725","obj":"T93033"},{"id":"R40528","pred":"arg2Of","subj":"T39668","obj":"T93033"},{"id":"R97670","pred":"arg1Of","subj":"T39668","obj":"T66151"},{"id":"R49090","pred":"arg1Of","subj":"T93033","obj":"T93255"},{"id":"R27028","pred":"arg2Of","subj":"T16710","obj":"T93255"},{"id":"R2338","pred":"arg1Of","subj":"T16710","obj":"T86610"},{"id":"R11456","pred":"arg2Of","subj":"T27148","obj":"T86610"},{"id":"R76677","pred":"arg1Of","subj":"T27148","obj":"T16499"},{"id":"R64079","pred":"arg1Of","subj":"T27148","obj":"T41273"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T55","span":{"begin":47,"end":59},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T56","span":{"begin":205,"end":221},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T57","span":{"begin":430,"end":435},"obj":"http://purl.obolibrary.org/obo/GO_0016265"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T213","span":{"begin":468,"end":476},"obj":"Body_part"},{"id":"T214","span":{"begin":504,"end":512},"obj":"Body_part"},{"id":"T215","span":{"begin":643,"end":651},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T211","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"T212","span":{"begin":47,"end":59},"obj":"Disease"},{"id":"T213","span":{"begin":307,"end":315},"obj":"Disease"},{"id":"T214","span":{"begin":413,"end":421},"obj":"Disease"},{"id":"T215","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"T216","span":{"begin":607,"end":615},"obj":"Disease"}],"attributes":[{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A214","pred":"mondo_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A213","pred":"mondo_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A216","pred":"mondo_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A215","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T50","span":{"begin":47,"end":59},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T51","span":{"begin":205,"end":221},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T50","span":{"begin":47,"end":59},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T51","span":{"begin":205,"end":221},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}

{"project":"LitCovid-sentences","denotations":[{"id":"T237","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T238","span":{"begin":61,"end":117},"obj":"Sentence"},{"id":"T239","span":{"begin":118,"end":230},"obj":"Sentence"},{"id":"T240","span":{"begin":231,"end":316},"obj":"Sentence"},{"id":"T241","span":{"begin":317,"end":436},"obj":"Sentence"},{"id":"T242","span":{"begin":437,"end":616},"obj":"Sentence"},{"id":"T243","span":{"begin":617,"end":728},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Evidence links COVID-19 to variable degrees of inflammation. Corticosteroids offer a potent anti-inflammatory option. However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels."}